Advanced Biologics Manufacturing for U.S. Strategic Readiness
Artificial intelligence is accelerating therapeutic discovery at an unprecedented pace. But in moments of national crisis, the limiting factor is not molecule design, it is the ability to manufacture those therapies quickly and securely within the United States.
- Defining the Problem
The Strategic Vulnerability
What America is facing today is a growing mismatch between rapid advances in biotechnology discovery and the domestic capacity required to manufacture those breakthroughs. Critical manufacturing infrastructure for advanced biologics remains globally distributed and strategically exposed.
- Advanced biologics manufacturing capacity remains concentrated offshore.
- High-potency payload and conjugation supply chains remain geopolitically exposed.
- AI-accelerated discovery is outpacing domestic production capacity.
“If AI designs the miracle drug but you can’t manufacture it domestically in a crisis, you don’t have a capability—you have a dependency.”
Thomas Axel Haag
Co-Founder & CEO
Linden Lake Labs
Xcellon Is Not a Commodity CDMO
Assured Domestic Capacity
Xcellon operates entirely within the United States with a secure supply chain strategy and facilities designed to safely manage high-potency biologic payloads.
Advanced Modality Expertise
Our team supports advanced therapeutic platforms including antibody-drug conjugates (ADC) and linker chemistry, multispecific antibodies, and T-cell engager constructs.
High-Potency Containment Infrastructure
Containment-rated cleanrooms and analytical platforms enable the safe development, characterization, and rapid prototyping of complex conjugated biologics.
Rapid Response Manufacturing
Xcellon’s manufacturing systems support rapid process adaptation, scalable transition from pilot production to clinical supply, and quality systems capable of supporting Emergency Use Authorization (EUA) programs.
Dual-Use Applications
Xcellon’s manufacturing capabilities support both commercial therapeutic development and national security applications. Advanced biologics platforms can be rapidly adapted to address emerging health threats, battlefield medicine needs, and biodefense initiatives.
Medical Countermeasures (MCM)
- Targeted toxin neutralization
- Payload-enabled antidote delivery
- Rapid retargeting platforms
Battlefield
Medicine
- Immune modulation constructs
- Infection control biologics
- Stable deployable formulations
Pandemic
Preparedness
- Rapid pathogen pivot capability
- Domestic stockpile manufacturing
- Emergency regulatory support
From Threat to Therapy
Identification
Engineering
Development
Characterization
Manufacturing
Support
Identification
Engineering
Development
Characterization
Manufacturing
Support
- NATIONAL STRATEGY ALIGNMENT
Alignment With U.S. Biotechnology Priorities
Xcellon’s infrastructure supports national biotechnology priorities by strengthening domestic biomanufacturing capacity, securing critical therapeutic supply chains, and enabling rapid deployment of advanced biologics. Our capabilities also accelerate the translation of biotechnology innovation into clinical and emergency response applications.
Government Engagement
For Government Program Managers
Medical countermeasures, biodefense platforms, domestic manufacturing partnerships.
For Defense Contractors
Teaming for prime/subcontract opportunities.
